Loading…
This event has ended. Create your own event on Sched.
Welcome to the Science Summit at UNGA76, a major contribution to advancing Science for the UN SDGs. Online from 14- September - 5 October 2021.
ISC will organise the second edition of the UNGA76 Science Summit around the 76th United Nations General Assembly (SSUNGA76) in September 2021. The objective of the virtual meeting will be to raise awareness of the role and contribution of science to the attainment of the United Nations Sustainable Development Goals. It will demonstrate initiatives that provide models for global science mechanisms and activities in support of the SDGs, particularly in science infrastructure and capacity building. Science is and will enable sustainable economic, environmental, and societal development. Science is more than a funding prioritisation exercise: science is impacting all areas of policy-making and is playing a more critical role in how policy objectives are achieved and the consequent benefit to people everywhere, including responses to global challenges.
Engagement with policy leadership is more important than ever: UNGA76 is a unique forum for science to demonstrate how policy and political leadership can benefit from innovation. Central to this is the role of nonstate actors and the multilateral fora, which increasingly determine how priorities are set. Science needs to be part of this dialogue and inform outputs through thought leadership, evidence, insights, analysis, and innovation.

Registration is available here.
avatar for Erik Ruuth

Erik Ruuth

IMiBio
Scientific Coordinator
Puerto Iguazú, Misiones
I am interested in the impact on Health of Biodiversity and climate change, and how to mitigate and heal changes. In other words, I see HEALTH as a wide concept that involves all our entire environment going from the organic to inorganic and how they interact.
The translation of scientific findings to animal and human health as well as the ecosystem homeostasis. How to conserve and to restore adequately our forests. How to decipher the play of actors in biological systems and the dynamics of these systems. Equally, it is of my interest how to generate large and small sustainable production systems, how to create adequate reforestation systems, and how to make live side-by-side small producers and large industries.

Erik Ruuth, M.D., PH.D., Ass. Prof. is a medical doctor with a Ph.D. in immunology and an adjunct professor in cell and molecular biology at Umeå University. After completing a postdoc at Hôpital Necker Enfants Malades in Paris, France, Erik made a career within the pharmaceutical industry covering areas ranging from basic industrial research to the molecular activities of new active principles, discoveries of mechanisms of action, preclinical development phases, pharmacokinetic toxicology, clinical registry studies, for authorities such as the FDA and EMA, ranging from PhI to III and post-marketing studies (PhIV). He assumed a number of responsibilities, as head of global research projects, head of EU therapeutic areas for anti-infectives, respiratory system and central nervous system products, head of development programs, expert in global products, project leader global research leader and leader of different types from PhI to PhIII clinical trials. As a consultant, ER has worked for the Ministry of Science and Technology of Argentina, for the National Cancer Institute in a large breast cancer project, consultant for the pharmaceutical and biotechnology industry. He is currently senior scientific advisor at the Madariaga Hospital in Posadas (Misiones), Principal Investigator at the Faculty of Medicine of the Catholic University of Misiones and Scientific Coordinator of the Misiones Institute for Biodiversity.

Erik Ruuth, M.D., PH.D., Ass. Prof., es médico, tiene un doctorado (Ph.D. ) en inmunología y es profesor adjunto en biología celular y molecular de la Universidad de Umeå. Su formación académica posgrado se efectuó en el conjunto de laboratorios que más tarde formaría el Laboratorio de Molecular de Infecciones de Suecia donde se efectuó parte del trabajo del Premio Nobel del año 2020. Luego de haber efectuado un postdoc en el Hôpital Necker Enfants Malades en Paris, Francia, Erik hizo una carrera dentro de la industria farmacéutica que abarcando áreas que van desde la investigación básica industrial de las actividades moleculares de nuevos principios activos, descubrimientos de mecanismos de acción, fases de desarrollo preclínico, farmacocinética toxicología, estudios de registro clínico, para autoridades como la FDA y la EMA, de PhI a III y estudios pos-marketing de PhIV. Asumió una serie de responsabilidades, como jefe de proyectos globales de investigación, jefe de áreas terapéuticas de la UE para anti-infectivos, productos del sistema respiratorio y del sistema nervioso central, jefe de programas de desarrollo, experto en productos globales, líder de proyectos de investigación global y líder de diferentes tipos de ensayos clínicos PhI, PhII y PhIII. Cómo consultor, ER ha trabajado para el Ministerio de Ciencia y Tecnología de Argentina, para el National Cancer Institute en un gran proyecto de cáncer de mama, consultor para la industria farmacéutica y biotecnológica. Actualmente es asesor científico senior del Hospital Madariaga en Posadas (Misiones) y del Instituto Misionero de Biodiversidad.